fluorouracil has been researched along with Atrophy, Muscle in 4 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cancer cachexia is common in many cancers and the loss of skeletal muscle mass compromises the response to therapies and quality of life." | 1.91 | Sulforaphane attenuates cancer cell-induced atrophy of C2C12 myotubes. ( Blazev, R; Li, W; Lynch, GS; Murphy, KT; Parker, BL; Swiderski, K; Trieu, J, 2023) |
| "Malnutrition is a common clinical symptom in cancer patients after chemotherapy, which is characterized by muscle wasting and metabolic dysregulation." | 1.56 | The gut microbiota attenuates muscle wasting by regulating energy metabolism in chemotherapy-induced malnutrition rats. ( Chen, H; Guo, Y; Liu, Y; Xu, C; Yao, Q; Zhang, F, 2020) |
| "Cachexia affects the majority of cancer patients, with currently no effective treatments." | 1.43 | Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. ( Barreto, R; Bonetto, A; Gao, H; Liu, Y; Waning, DL; Zimmers, TA, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, W | 1 |
| Trieu, J | 1 |
| Blazev, R | 1 |
| Parker, BL | 1 |
| Murphy, KT | 1 |
| Swiderski, K | 1 |
| Lynch, GS | 1 |
| Chen, H | 1 |
| Xu, C | 1 |
| Zhang, F | 1 |
| Liu, Y | 2 |
| Guo, Y | 1 |
| Yao, Q | 1 |
| Köstek, O | 1 |
| Demircan, NC | 1 |
| Gökyer, A | 1 |
| Küçükarda, A | 1 |
| Sunal, BS | 1 |
| Hacıoğlu, MB | 1 |
| Eslame, H | 1 |
| Solak, S | 1 |
| Yılmaz, E | 1 |
| Uzunoğlu, S | 1 |
| Tunçbilek, N | 1 |
| Çiçin, I | 1 |
| Erdoğan, B | 1 |
| Barreto, R | 1 |
| Waning, DL | 1 |
| Gao, H | 1 |
| Zimmers, TA | 1 |
| Bonetto, A | 1 |
4 other studies available for fluorouracil and Atrophy, Muscle
| Article | Year |
|---|---|
Sulforaphane attenuates cancer cell-induced atrophy of C2C12 myotubes.
Topics: Antioxidants; Dimethyl Sulfoxide; Fluorouracil; Humans; Muscle Fibers, Skeletal; Muscular Atrophy; N | 2023 |
The gut microbiota attenuates muscle wasting by regulating energy metabolism in chemotherapy-induced malnutrition rats.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Energy Metabolism; Fecal Microbiota Transplan | 2020 |
Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2019 |
Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs.
Topics: Activin Receptors, Type II; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Compositio | 2016 |